Keyword: Gilead Sciences

Four drug companies have canceled or reduced price increases after a drug pricing law in California took effect, according to Bloomberg.

Eisai and Celgene veteran Michael Amoroso will take on the challenge of making Gilead's entrance into CAR-T cancer treatments a success.

Roche sued Lilly Tuesday, claiming the two-year-old psoriasis med Taltz steps on one of its patents. Thing is, Roche just won that patent this week.

Gilead and Novartis CAR-T cancer drugs Yescarta and Kymriah won an EMA committee backing for marketing approval.

Cost-effectiveness watchdog ICER routinely reviews new drug prices, but now it's aiming to unveil price hikes on older meds.

Spectrum Pharma—a rare disease and cancer specialist with six marketed drugs and $116 million in annual sales—is eyeing a sale, Bloomberg says. 

Higher salary and more room for growth under an entrepreneurial environment are driving Chinese global pharma executives to domestic biotechs.

Amid an industrywide probe, Lundbeck reached a tentative settlement wrapping up its own copay charity allegations.

Gilead's promotion of Andrew Dickinson, and a fresh licensing deal, could signal that Gilead's looking outside its own walls for growth opportunities.

In Gilead's new TV awareness ads for HIV prevention, actors talk “honestly” about fearing HIV testing and having unprotected sex.